@article{67e299eb31934e91969fffd349523420,
title = "A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer{\textquoteright}s disease",
abstract = "Trial registration : ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic.clinicaltrials.gov/ct2/show/NCT05821153.",
keywords = "Humans, Alzheimer Disease/drug therapy, Pilot Projects, Treatment Outcome, Immunotherapy",
author = "Alireza Faridar and Eid, {Abdulmunaim M} and Thome, {Aaron D} and Weihua Zhao and Beers, {David R} and Pascual, {Maria B} and Nakawah, {Mohammad O} and Roman, {Gustavo C} and Davis, {Charles S} and Michael Grundman and Masdeu, {Joseph C} and Appel, {Stanley H}",
note = "Funding Information: This research was supported by the Alzheimer{\textquoteright}s Association Part-The-Cloud Award, the Houston Methodist Clinical Scholar Award and a fund from MD Anderson Foundation. Funding Information: The authors appreciate the assistance of Jennifer M. Garrett, Rejani R. Nair, Jinghong Wang and Shixiang Wen of the Houston Methodist Neurological Institute and the Nantz National Alzheimer Center. We are grateful to the Nantz National Alzheimer Center patients and families for making this research possible. Publisher Copyright: {\textcopyright} 2023, The Author(s).",
year = "2023",
month = nov,
day = "16",
doi = "10.1186/s40035-023-00387-5",
language = "English (US)",
volume = "12",
pages = "54",
journal = "Translational Neurodegeneration",
issn = "2047-9158",
publisher = "BioMed Central",
number = "1",
}